Peripheral Vascular Devices Market

Market Overview

According to Kings Research, the global peripheral vascular devices market size was valued at USD 11.48 billion in 2025 and is projected to reach USD 20.30 billion by 2033, exhibiting a CAGR of 7.39% during the forecast period (2026-2033).

Market expansion is driven by the rising prevalence of peripheral artery disease, increasing adoption of minimally invasive endovascular procedures, and technological advancements in angioplasty, stent, and atherectomy devices. Expansion of outpatient care settings and ongoing improvements in vascular intervention infrastructure are further driving this growth.

Kings Research estimates that these drivers, together with rising disease awareness and expanding reimbursement coverage in key markets, are jointly reinforcing procedure volumes across hospital and outpatient settings.

These estimates are based on Kings Research’s proprietary research methodology, which combines primary interviews with industry participants, secondary research across published market reports and regulatory filings, and validation against public company disclosures.

Key Market Highlights

• According to Kings Research, the global peripheral vascular devices market was valued at USD 11.48 billion in 2025.
• The market is projected to grow at a CAGR of 7.39% from 2026 to 2033.
• North America held a share of 41.23% in 2025, valued at USD 4.73 billion, and is anticipated to register a CAGR of 6.61% over the forecast interval.
• The angioplasty devices segment garnered USD 3.83 billion in revenue in 2025.
• The peripheral artery disease segment is expected to reach USD 8.70 billion by 2033.
• The ambulatory surgical centers segment is anticipated to witness the fastest CAGR of 7.21% over the forecast period.
• Asia Pacific is expected to grow at a CAGR of 6.89% during the projection period.

Market Dynamics

What Factors Are Driving Demand For Peripheral Vascular Devices In The Treatment Of Vascular Disorders?

The rising prevalence of peripheral artery disease and other vascular disorders boosts demand for peripheral vascular devices, driven by increasing rates of diabetes, obesity, hypertension, smoking, and an aging population.

The growing incidence of arterial occlusions, aneurysms, and venous complications is raising the demand for angioplasty balloons, stents, and atherectomy systems to restore blood flow and reduce procedural risks. Improving disease awareness, earlier diagnosis, and the growing adoption of minimally invasive endovascular treatments are further supporting market growth.

According to the U.S. Centers for Disease Control and Prevention (CDC), peripheral artery disease affects approximately 6.5 million adults aged 40 years and older in the U.S., with prevalence increasing significantly among individuals aged 60+, diabetics, and those with a history of smoking.

How Do High Costs And Procedural Complexity Restrain The Peripheral Vascular Devices Market?

A key challenge restraining the growth of the peripheral vascular devices market is the high cost and procedural complexity associated with advanced endovascular interventions. Adoption of next-generation stents, atherectomy systems, imaging-guided devices, and specialty catheters requires significant capital investment, specialized infrastructure, and highly trained interventional specialists.

Additionally, procedural variability, reimbursement limitations, and device selection complexity increase operational burden for healthcare providers. These factors limit adoption among smaller hospitals, ambulatory surgical centers, and healthcare systems in cost-sensitive and emerging markets.

To address this challenge, market participants are focusing on device miniaturization, simplified delivery systems, and integrated platform designs that reduce procedural complexity. Manufacturers are also expanding physician training programs, clinical education initiatives, and partnerships with healthcare providers to improve procedural efficiency, support skill development, and enable broader adoption of peripheral vascular devices across diverse care settings.

How Are Next Generation Peripheral Vascular Devices Transforming Outcomes And Safety In Minimally Invasive Vascular Procedures?

Continued innovation in device design, drug delivery, lesion preparation, and procedural guidance to improve treatment precision, durability, and patient safety is transforming the market. Healthcare providers are increasingly adopting next-generation stents, drug-coated balloons (DCBs), atherectomy systems, thrombectomy devices, and endovascular aneurysm repair (EVAR) technologies incorporating advanced materials, drug-delivery coatings, improved catheter designs, and enhanced delivery and imaging capabilities.

These innovations are intended to improve device navigability and deployment accuracy, optimize lesion preparation and drug delivery, reduce vessel trauma and procedural complications, and improve longer-term vessel patency. As these technologies become more integrated into routine endovascular workflows, they are supporting more predictable minimally invasive treatment and expanding the use of peripheral vascular interventions across hospital and outpatient settings.

• In June 2025, the U.S. FDA approved a PMA supplement for Surmodics’ SurVeil Drug-Coated Balloon, incorporating final post-approval study data into its labeling. The development strengthens the clinical evidence base for drug-coated balloon technology in peripheral vascular interventions and supports its continued use in minimally invasive treatment.

Market Segmentation

Segmental Analysis

Which Product Type Captures The Highest Market Valuation In The Peripheral Vascular Devices Market?

The angioplasty devices segment earned USD 3.83 billion in 2025, mainly due to high peripheral artery disease procedure volumes and the widespread adoption of drug-coated balloons to reduce restenosis and improve long-term outcomes. The Others product-type category includes guidewires, vascular closure devices, and introducer sheaths used to support angioplasty, stenting, and atherectomy procedures.

Which Application Type Held The Maximum Market Share In 2025?

The peripheral artery disease segment held a share of 45.32% in 2025, driven by the high prevalence of PAD globally and the frequent need for repeat endovascular interventions using angioplasty, stenting, and atherectomy devices. The Others application category includes iliac artery disease and other less-prevalent peripheral vascular conditions treated using similar endovascular device types.

Which End User Segment Is Anticipated To Register The Fastest Growth Rate Over The Forecast Period?

The hospital's end-use segment is projected to reach USD 10.63 billion by 2033. The high growth rate is attributed to a high volume of complex peripheral vascular procedures, advanced interventional infrastructure, and specialized vascular care teams.

Regional Analysis

What Is The Market Scenario Across Key Regions In The Global Peripheral Vascular Devices Market?

Based on region, the market has been classified into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America.

North America's peripheral vascular devices market share stood at 41.23% in 2025, with a valuation of USD 4.73 billion. This dominance is reinforced by a high prevalence of peripheral artery disease, well-established interventional infrastructure, and strong adoption of advanced endovascular technologies.

The U.S. leads regional demand, propelled by an aging population, a high burden of diabetes and cardiovascular risk factors, and broad access to minimally invasive treatments. Favorable reimbursement coverage for peripheral interventions and early adoption of drug-coated balloons, atherectomy systems, and advanced catheter technologies further support domestic market growth.

• In July 2025, Teleflex Incorporated acquired BIOTRONIK’s Vascular Intervention business for nearly USD 886.7 million, expanding its coronary and peripheral intervention portfolio and global cath-lab presence. The acquisition is expected to strengthen Teleflex’s pipeline through technologies such as Freesolve, which is a resorbable coronary scaffold.

The Asia-Pacific peripheral vascular devices industry is set to grow at a CAGR of 6.89% over the forecast period. This rapid growth is propelled by an expanding patient population and improving access to interventional vascular care.

The rising prevalence of peripheral artery disease, diabetes, and lifestyle-related cardiovascular risk factors is increasing demand for peripheral interventions across major economies such as China, India, and Japan. Ongoing investments in hospital infrastructure, expansion of catheterization laboratories, and growing adoption of minimally invasive endovascular procedures are further supporting regional market expansion.

For instance, in February 2025, Shanghai Tendfo Medical Device Co., Ltd. received approval from the China National Medical Products Administration (NMPA) for its Tendvia Pulmonary Artery Thrombectomy System. The device is indicated for transcatheter thrombectomy in patients with acute high-risk or intermediate-risk pulmonary embolism, offering a minimally invasive option for critically ill patients.

Europe is forecasted to witness steady market growth, driven by the rising prevalence of peripheral artery disease, an aging population, and increasing adoption of minimally invasive vascular procedures.

The Middle East & Africa market is projected to grow at a steady pace, supported by the increasing burden of diabetes and cardiovascular diseases, improving healthcare infrastructure, and greater access to advanced vascular interventions. South and Central America is anticipated to experience moderate growth, fueled by rising cardiovascular risk factors, improving healthcare access, and increasing adoption of minimally invasive peripheral vascular procedures.

Regulatory Frameworks

• In the U.S., peripheral vascular devices are regulated by the U.S. Food and Drug Administration (FDA) under medical device regulations. Products such as angioplasty balloons, stents, atherectomy systems, and embolic protection devices require 510(k) clearance or Premarket Approval (PMA), depending on risk classification. The FDA evaluates these devices for safety, performance, clinical effectiveness, and manufacturing quality before market authorization.
• In the European Union, peripheral vascular devices are governed under the Medical Device Regulation (MDR), which imposes stricter requirements for clinical evidence, risk management, and post-market surveillance compared to the former MDD framework.
• Across the Asia-Pacific region, China regulates peripheral vascular devices through the National Medical Products Administration (NMPA), emphasizing local clinical evaluation, product testing, and quality compliance.
• Globally, organizations such as the International Medical Device Regulators Forum (IMDRF) promote regulatory harmonization, convergence of safety standards, and best practices for medical device evaluation. These efforts facilitate international market access and improve post-market surveillance for peripheral vascular devices worldwide.

Competitive Landscape

How Is The Introduction Of New Peripheral Vascular Devices Changing Competition In Emerging Markets?

Leading players operating in the peripheral vascular devices industry are focusing on technological innovation, portfolio expansion, and procedural efficiency to strengthen their competitive position. Major manufacturers are investing in next-generation stents, drug-coated balloons, atherectomy systems, and specialty catheters to improve deliverability, durability, and clinical outcomes in complex peripheral interventions.

Companies are increasingly integrating imaging compatibility, enhanced coatings, and advanced materials into device design to support minimally invasive procedures and reduce complication rates.

• In July 2025, MicroPort Endovastec reported the first commercial use of its Talos Thoracic Stent Graft System in Argentina to treat a Stanford type B aortic dissection. The procedure employed a single, personalized stent graft to restore blood flow while reducing the risk of spinal cord ischemia.
• In July 2025, Cook Medical announced the U.S. commercial availability of its Zenith Iliac Branch Device (ZBIS) following FDA approval in May 2025. The device provides an endovascular treatment option for aortoiliac and iliac aneurysms while preserving blood flow to the internal iliac artery.
• In March 2025, Boston Scientific introduced an enhanced FilterWire EZ embolic protection system in select European markets. The updated system incorporates a guidewire with a 110-micron pore filter at the distal tip, designed to capture embolic debris while preserving blood flow and ensuring consistent vessel wall apposition during peripheral vascular interventions.

Who Are The Key Market Players In The Global Peripheral Vascular Devices Market?

• Abbott
• AngioDynamics
• BD
• Boston Scientific Corporation
• Braun SE
• Cardinal Health
• Cook
• Cordis
• Getinge AB
• Koninklijke Philips N.V.
• Gore & Associates, Inc.
• Medtronic
• Merit Medical Systems
• Penumbra, Inc
• Terumo Corporation

Research Methodology

How We Gather This Information

Our methodology triangulates insights from multiple independent and publicly available research databases, which is further validated against regulatory filings and public company disclosures. All estimates are cross-verified; no single-source data is presented without validation.

Data collection combines primary interviews with industry participants, including device manufacturers, clinicians, and channel partners, with secondary research across published market reports, regulatory filings, and proprietary databases, applying a combined bottom-up and top-down approach with additional validation from subject matter experts before final quality review.

Why Kings Research?

Our custom offerings deliver tailored, data-driven intelligence and strategic guidance to help organizations identify, evaluate, and capitalize on key market opportunities.